AcariaHealth is proud to partner with argenx Pharmaceuticals to bring patients an innovative new treatment option: VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc), a prefilled syringe for self-injection. This new formulation offers adults living with generalized myasthenia gravis (gMG), who are anti-acetylcholine receptor (AChR) antibody positive, and those with chronic inflammatory demyelinating polyneuropathy (CIDP) a more flexible, convenientway to manage their condition.

Together with argenx, we are committed to not only expanding access to advanced therapies but also providing compassionate, personalized care throughout every stage of the patient journey.

Empowering Patients with Treatment on Their Own Terms

The VYVGART HYTRULO prefilled syringe is a 20–30 second subcutaneous injection designed for administration by patients, caregivers, or healthcare professionals. After receiving appropriate training, patients can self-administer the medication, giving them more autonomy in managing their treatment.

This at-home option introduces a new level of flexibility, allowing patients to choose when and where they receive treatment; whether it’s in the comfort of home, a physician’s office, or while traveling. The ability to self-inject not only reduces the burden of frequent clinic visits but also helps patients fit treatment more easily into their lives.

For individuals living with gMG or CIDP, the symptoms and treatment logistics can be profoundly disruptive. This new self-injection option represents a meaningful step forward, allowing patients to reclaim valuable time, reduce disruptions to daily life, and maintain consistent treatment.

Understanding the Conditions

Generalized Myasthenia Gravis (gMG)
gMG is a rare, chronic autoimmune neuromuscular disorder where IgG autoantibodies impair communication between nerves and muscles, resulting in severe and potentially life-threatening muscle weakness. Approximately 85% of people with myasthenia gravis will progress to gMG within 24 months. Among these, about 85% test positive for AChR antibodies.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CIDP is a rare autoimmune disorder that affects the peripheral nervous system, leading to nerve damage and loss of muscle strength and sensation. Many patients experience progressive or relapsing symptoms, such as fatigue, weakness, and sensory loss in the limbs. Without treatment, one-third of patients may eventually require a wheelchair. Evidence increasingly suggests a significant role of IgG antibodies in the disease’s progression.

Personalized Support, Every Step of the Way

At AcariaHealth, we understand the unique challenges faced by patients managing complex, chronic conditions. That’s why we go beyond medication access—providing expert guidance, personalized support, and dependable service tailored to each individual’s needs.

Our experienced pharmacists and clinicians collaborate closely with patients and healthcare teams to ensure smooth onboarding, reliable delivery, and comprehensive care.From prescription through ongoing support, we are your trusted partner on the path to better health.

Learn More

Explore more information and support resources:

• vyvgart.com – For patients and families
• vyvgarthcp.com – For healthcare professionals

Stay informed about the latest in specialty pharmacy by following AcariaHealth on LinkedIn.